CELC | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 1%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.01%

1 Month

-11.14%

3 Months

5.70%

6 Months

1.40%

1 Year

65.90%

2 Year

59.60%

Key data

Stock price

$15.97

P/E Ratio

0.00

DAY RANGE

N/A - $16.34

EPS

$0.00

52 WEEK RANGE

$8.39 - $22.19

52 WEEK CHANGE

$0.62

MARKET CAP

591.001 M

YIELD

N/A

SHARES OUTSTANDING

37.030 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/14/2024

BETA

1.08

PUBLIC FLOAT

AVERAGE 10 VOLUME

$411,844

AVERAGE 30 VOLUME

$358,747

Company detail

CEO:
Region: US
Website: celcuity.com
Employees: 41
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.

CELC - Celcuity Inc